Compare Koninklijke Philips NV (PHG) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs 10X Genomics Inc — how do they compare? Koninklijke Philips NV trades at $25.03 (market cap $24.84B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: Koninklijke Philips NV is far larger — about 2.9× 10X Genomics Inc's market cap, and Koninklijke Philips NV pays a 4.01% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| PHG | TXG | |
|---|---|---|
Market Cap | $24.84B | $8.55B |
Sector | Health | Health |
52-Week High | $32.91 | $67.29 |
52-Week Low | $25.02 | $11.34 |
Enterprise Value | $31.44B | $8.08B |
Dividend Yield | 4.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $25.29, down 2.32% today, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.57 versus $0.40 expected, continuing a trend of profitability after a turnaround from losses in prior years. Recent news highlights product launches in health technology and a $33.7 million award for AI-enabled stroke care (Business Wire, 2026-08-26).
The outlook is mixed: fundamentals show improving margins and cash flow, but technical indicators and a majority hold analyst rating suggest near-term caution. Key risks include competitive pressures and execution of growth initiatives, while institutional buying activity indicates underlying confidence.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
